China Pharma Holdings Inc. (CPHI) exhibits -3.2% gross margins and -11.4% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 24.0x enterprise multiple and 4.8% implied options volatility.
Sustained -3.2% gross profitability converts into -60.0% operating margin and -11.4% ROIC, outpacing sector cost of capital.
ROIC: -11.4% // GM: -3.2%YoY revenue trajectory of -8.5% paired with 0.32% free cash flow yield supports self-funded R&D and capital return.
REV YOY: -8.5% // FCF YLD: 0.32%Altman Z-Score of 0.20 and Piotroski F-Score of 4/9 indicate low near-term refinancing stress.
ALTMAN Z: 0.20 // F-SCORE: 4/9Trading at 24.0x trailing P/E (— Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±5.2% implied move with a 0.85 put/call ratio around $0.65 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend -60.0% net margins.
NET MARGIN: -60.0% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for CPHI & activate live FRED threshold breach alerts.